This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2023 Jan;11(1):e5-e6.

doi: 10.1016/S2213-2600(22)00452-0. Epub 2022 Dec 12.

Cardiac and vascular serious adverse events following tixagevimab-cilgavimab

Jolanta Piszczek¹, Srinivas Murthy², Kevin Afra³

Affiliations

Affiliations

¹ Faculty of Pharmacy, University of British Columbia, Vancouver V6T 1Z3, BC, Canada. Electronic address: jpiszcze@mail.ubc.ca.
² Division of Pediatrics, University of British Columbia, Vancouver V6T 1Z3, BC, Canada.
³ Division of Infectious Diseases, University of British Columbia, Vancouver V6T 1Z3, BC, Canada.

PMID: 36521510
DOI: 10.1016/S2213-2600(22)00452-0

Comment

Cardiac and vascular serious adverse events following tixagevimab-cilgavimab

Jolanta Piszczek et al. Lancet Respir Med. 2023 Jan.

. 2023 Jan;11(1):e5-e6.

doi: 10.1016/S2213-2600(22)00452-0. Epub 2022 Dec 12.

Authors

Jolanta Piszczek¹, Srinivas Murthy², Kevin Afra³

Affiliations

¹ Faculty of Pharmacy, University of British Columbia, Vancouver V6T 1Z3, BC, Canada. Electronic address: jpiszcze@mail.ubc.ca.
² Division of Pediatrics, University of British Columbia, Vancouver V6T 1Z3, BC, Canada.
³ Division of Infectious Diseases, University of British Columbia, Vancouver V6T 1Z3, BC, Canada.

PMID: 36521510
DOI: 10.1016/S2213-2600(22)00452-0

No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Comment in

Cardiac and vascular serious adverse events following tixagevimab-cilgavimab - Author's reply.
Maselkar S, Kiazand A, Templeton A, Montgomery H, Esser MT. Maselkar S, et al. Lancet Respir Med. 2023 Jan;11(1):e7-e8. doi: 10.1016/S2213-2600(22)00450-7. Epub 2022 Dec 12. Lancet Respir Med. 2023. PMID: 36521509 Free PMC article. No abstract available.

Comment on

Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial.
ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group. ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Lancet Respir Med. 2022 Oct;10(10):972-984. doi: 10.1016/S2213-2600(22)00215-6. Epub 2022 Jul 8. Lancet Respir Med. 2022. PMID: 35817072 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science